HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Authors:
Open Access
- 1 April 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 6 (4) , e196496
Abstract
Advanced prostate cancer treatment with androgen deprivation therapy (ADT) via medical or surgical castration depletes circulating gonadal testosterone levels and nearly always produces initial clinical responses. However, castration-resistant prostate cancer (CRPC) eventually develops, typically by revived signaling through the androgen receptor pathway.1 A major mechanism of androgen receptor restimulation is tumor synthesis of testosterone or dihydrotestosterone from extragonadal precursor steroids, including adrenal dehydroepiandrosterone and its respective sulfate.2 The critical role of precursor steroids has been clinically validated by the survival benefit conferred by abiraterone, which blocks extragonadal androgen synthesis by inhibiting 17α-hydroxylase/17,20-lyase.3,4Keywords
This publication has 38 references indexed in Scilit:
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancerNature, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate CancerCell, 2013
- Minireview: Androgen Metabolism in Castration-Resistant Prostate CancerMolecular Endocrinology, 2013
- Intermittent versus Continuous Androgen Deprivation in Prostate CancerNew England Journal of Medicine, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- 3β-Hydroxysteroid Dehydrogenase Is a Possible Pharmacological Target in the Treatment of Castration-Resistant Prostate CancerEndocrinology, 2010
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000